600566.SS SHH
Hubei Jumpcan Pharmaceutical Co., Ltd.
1W: +3.6%
1M: -1.0%
3M: +14.2%
YTD: -5.8%
1Y: -3.1%
3Y: +6.2%
5Y: +71.1%
¥25.63 ($3.82)
+0.76 (+3.06%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$18.5B
+1.7% ▲
5Y CAGR: +16.3%
Total Liabilities
$3.7B
-21.8% ▼
5Y CAGR: +7.8%
Shareholders Equity
$14.7B
+10.1% ▲
5Y CAGR: +19.2%
Cash & Investments
$11.8B
+8.4% ▲
5Y CAGR: +36.7%
Total Debt
$788M
-24.5% ▼
5Y CAGR: +6.4%
Net Debt
-$5.9B
+4.4% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $3.0B | $3.8B | $4.8B | $7.7B | $6.7B |
| Short-Term Investments | $1.3B | $1.7B | $3.0B | $3.2B | $5.2B |
| Cash & ST Investments | $4.2B | $5.5B | $7.9B | $10.9B | $11.8B |
| Net Receivables | $2.1B | $2.2B | $2.9B | $2.8B | $2.3B |
| Inventory | $278M | $376M | $391M | $490M | $569M |
| Other Current Assets | $10M | $70M | $71M | $7M | $6M |
| Total Current Assets | $6.6B | $8.1B | $11.2B | $14.2B | $14.7B |
| Property, Plant & Equip. | $3.1B | $3.0B | $2.9B | $3.0B | $2.7B |
| Goodwill & Intangibles | $451M | $447M | $488M | $483M | $478M |
| Long-Term Investments | -$1.1B | -$1.3B | -$2.7B | $394M | -$4.7B |
| Other Non-Current Assets | $1.4B | $1.8B | $3.1B | $8M | $5.2B |
| Total Non-Current Assets | $3.9B | $4.0B | $3.8B | $3.9B | $3.8B |
| Total Assets | $10.5B | $12.1B | $15.0B | $18.1B | $18.5B |
| — Liabilities — | |||||
| Accounts Payable | $658M | $946M | $39M | $2.1B | $1.7B |
| Short-Term Debt | $1M | $0 | $400M | $1.0B | $787M |
| Deferred Revenue | $1.2B | $1.2B | $49M | $0 | $0 |
| Other Current Liabilities | $3M | $651M | $1.4B | $1.4B | $70M |
| Total Current Liabilities | $2.0B | $2.8B | $3.4B | $4.6B | $3.5B |
| Long-Term Debt | $603M | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $4M | $1M | $1M | $820K | $531K |
| Total Non-Current Liabilities | $786M | $199M | $201M | $183M | $195M |
| Total Liabilities | $2.8B | $3.0B | $3.6B | $4.8B | $3.7B |
| — Equity — | |||||
| Common Stock | $436M | $436M | $453M | $453M | $453M |
| Retained Earnings | $4.0B | $5.3B | $6.8B | $8.8B | $10.2B |
| Accumulated OCI | $153M | $153M | -$57M | $0 | $0 |
| Total Stockholders Equity | $7.8B | $9.1B | $11.3B | $13.3B | $14.7B |
| Total Liabilities & Equity | $10.5B | $12.1B | $15.0B | $18.1B | $18.5B |
| — Key Metrics — | |||||
| Total Debt | $604M | $630M | $401M | $1.0B | $788M |
| Net Debt | -$2.4B | -$3.2B | -$4.4B | -$6.2B | -$5.9B |
| Total Investments | $155M | $328M | $332M | $3.6B | $465M |